Brian Daniels
Member of the Board and member
Board of Directors
Novo Nordisk
Denmark
Biography
Dr Daniels was first elected to the Board of Novo Nordisk A/S in 2016 and has most recently been re-elected in March 2017. His term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Dr Daniels is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. In January 2017, the Board of Directors also assessed that the special competencies possessed by Dr Daniels that are important for the performance of his duties are his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutics areas within the pharmaceutical industry, especially in the US.
Research Interest
Clinical development, medical affairs
